Literature DB >> 3149100

[Prolactin stimulation using the metoclopramide test in females taking oral contraceptives].

W Carol1, H Lauterbach, G Klinger, A Unger, W Michels.   

Abstract

In 31 patients taking oral contraceptives (o.c.) for a period between 1 year to more than 3 years, basal serum prolactin levels and metoclopramide induced prolactin values were determined 30 and 60 minutes following an i.v. injection of 10 mg of metoclopramide. The basal prolactin levels were elevated in 7 women to more than 1,000 mU l. The 3 groups of patients taking o.c. with different estrogen doses showed higher drug induced increase of their prolactin levels than the controls. These differences were statistically significant between groups I and III and the control group. No differences could be found between the challenged values of the users groups. The prolactin increase challenged with 200 micrograms TRH in 5 women under o.c. was considerably smaller than that observed in the metoclopramide groups, but exceeded the TRH induced levels found in the controls. The significance of these findings is discussed with special reference to the promotion of prolactinomas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3149100

Source DB:  PubMed          Journal:  Zentralbl Gynakol        ISSN: 0044-4197


  5 in total

Review 1.  Genesis of prolactinomas: studies using estrogen-treated animals.

Authors:  Dipak K Sarkar
Journal:  Front Horm Res       Date:  2006       Impact factor: 2.606

2.  Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line.

Authors:  Hongtao Lv; Chuzhong Li; Songbai Gui; Meizhen Sun; Dan Li; Yazhuo Zhang
Journal:  J Neurooncol       Date:  2010-08-11       Impact factor: 4.130

3.  Involvement of protein kinase C-dependent mitogen-activated protein kinase p44/42 signaling pathway for cross-talk between estradiol and transforming growth factor-beta3 in increasing basic fibroblast growth factor in folliculostellate cells.

Authors:  Kirti Chaturvedi; Dipak K Sarkar
Journal:  Endocrinology       Date:  2003-11-06       Impact factor: 4.736

Review 4.  Potential of gene therapy for the treatment of pituitary tumors.

Authors:  R G Goya; D K Sarkar; O A Brown; C B Hereñú
Journal:  Curr Gene Ther       Date:  2004-03       Impact factor: 4.391

5.  Insulin-like growth factor-I gene therapy reverses morphologic changes and reduces hyperprolactinemia in experimental rat prolactinomas.

Authors:  Gloria M Console; Claudia B Herenu; Gisela A Camihort; Georgina C Luna; Maria I Bracamonte; Gustavo R Morel; Rodolfo G Goya
Journal:  Mol Cancer       Date:  2008-01-25       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.